Gilead Sciences to acquire Arcellx for $7.8bn.

Gilead Sciences, an American biopharmaceutical company headquartered in Foster City, California, agreed to acquire Arcellx, a clinical-stage biotech company, for $7.8bn. "This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma. Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy. In addition, the anito-cel D-domain BCMA binder could be important to our work in in vivo cell therapy, further strengthening our potential in oncology and inflammation," Daniel O’Day, Gilead Sciences Chairman and CEO.